Sex differences among elderly patients with acute coronary syndrome undergoing percutaneous coronary intervention receiving ticagrelor 60 mg vs. 90 mg: a post-hoc analysis of a randomized trial

View at publisher Summarise with VIRAT
Authors: Alberto Laino, Mario Enrico Canonico, Fiorenzo Simonetti, Marisa Avvedimento, A P Vitale, Anna Franzone, Giuseppe Gargiulo, Plinio Lorenzo Cirillo, Giovanni Esposito, Raffaele Piccolo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background No sex-based data are available on the pharmacodynamic and pharmacokinetic profile of ticagrelor 60 mg twice daily as alternative to its standard dose during the early phase after acute coronary syndrome (ACS). Methods This post-hoc study is a sex-based secondary analysis of the PLINY THE ELDER randomized, crossover trial (NCT04739384), which compared ticagrelor 60 vs. 90 mg in elderly patients with ACS undergoing percutaneous coronary intervention (PCI). The primary endpoint was the pre-dose P2Y12 reaction units (PRU) using the VerifyNow-P2Y12 (Accumetrics, San Diego, CA, USA) at 14 days after treatment with ticagrelor 60 or 90 mg twice daily. Results A total of 50 elderly patients with ACS was included in the study. Of these patients, 28 (56%) were males and 22 (44%) females. The two doses of ticagrelor had a comparable pre-dose PRU in both males (pre-dose: LSM difference60 vs. 90 -7.00, 95%CI -25.3 to 11.3, p =0.44) and females (pre-dose: LSM difference60 vs. 90 -0.89, 95%CI -20.3 to 18.5, p =0.93), with no evidence of sex-based interaction (pre-dose: p for interaction =0.88). Consistently, transmittance aggregometry and multiple electrode aggregometry showed a similar pharmacodynamic profile between the two doses of ticagrelor in both male and female patients. Plasma levels of ticagrelor were significantly lower using the reduced dose of ticagrelor as compared with the standard dose in both males (pre-dose: LSM difference60 vs. 90 -212, 95%CI -391 to -33.0, p

Fields of Study & Subjects

Antiplatelet Therapy and Cardiovascular Diseases Sex and Gender in Healthcare Acute Myocardial Infarction Research

Publication details

Journal / source
European Heart Journal Supplements
Volume
28
Issue
Supplement_3
Pages
suag056.166
Publication date
1 March 2026
Language
EN